Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UKIssue Date
2023
Metadata
Show full item recordAbstract
Therapeutic options for patients with relapsed SCLC are limited, and the prognosis in this setting remains poor. While clinical outcomes for frontline treatment have modestly improved with the introduction of immunotherapy, treatment in the second-line setting persists almost unchanged. In this review, current treatment options and recent advances in molecular biology are described. Emerging therapeutic options in this setting, and potential strategies to improve clinical outcomes of these patients are also addressed.Citation
Moliner L, Zhang B, Lamberti G, Ardizzoni A, Byers LA, Califano R. Novel therapeutic strategies for recurrent SCLC. Crit Rev Oncol Hematol. 2023 Jun;186:104017. PubMed PMID: 37150311. Epub 2023/05/08. eng.Journal
Critical Reviews in Oncology/HaematologyDOI
10.1016/j.critrevonc.2023.104017PubMed ID
37150311Additional Links
https://dx.doi.org/10.1016/j.critrevonc.2023.104017Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.critrevonc.2023.104017